Agents and Actions

Editors
K. Brune (Executive Editor)
I. Ahnfelt-Rønne
R. O. Day
H. O. Handwerker
A. Lewis
W. Lorenz
I. Otterness

Index to volume 34, 1991

Birkhäuser Verlag
CH-4010 Basel (Switzerland)
© 1991

Author Index

Adams, L. M., 223
Adelson, D., 302
Amdahl, L., 70
Anania, T., 244
Anderson, C. M., 81
Anderson, D. W., 247
Anglin, C. P., 5, 178
Argenbright, L. W., 208
Argentieri, D., 247
Arleth, A., 205
Arner, E. C., 60

Bachmann, H., 11
Baeder, W. L., 220
Bak, C. E. T., 81
Bandara, G., 285
Baron, D. A., 30
Bartlett, R. R., 151
Barton, R. W., 208, 211
Bassett, D. J. P., 270
Bendele, A. M., 56, 194, 254
Benslay, D. N., 100, 254
Berbiguier, N., 424
Berg, R. A., 8
Berkenkopf, J. W., 93, 97
Bethke, P., 393
Bianco E. del, 376
Bird, T. G. C., 110
Blancuzzi, V., 46, 129, 214, 226, 232, 239
Bolin, D. R., 77
Bolognese, B., 106
Borella, L., 220, 223
Borgeat, P., 32, 117
Bourgoin, S., 32
Brattsand, R., 35, 200
Breider, M. A., 197
Brooks, R. H., 169
Bürger, W., 358
Buckman, D., 181
Burch, R. M., 142, 191, 229
Bureau, M., 203
Burrows, J. C., 350

Caccese, R., 220, 223
Calhoun, W., 20
Capetola, R. J., 247
Capodici, C., 8
Carlson, R. P., 20, 84, 235
Cashin, C. H., 332
Cavigioli, G., 309
Chander, C. L., 282
Chandrasekhar, S., 56
Chang, J. Y., 89
Chau, T. T., 20, 84, 235
Chen, X., 397
Chertock, H., 125
Chesonis, R. S., 187
Chiba, K., 242
Cho, M., 350
Cicala, C., 247
Cirino, G., 247
Clapp, N. K., 178
Clark, D. A., 175, 185
Clearfield, H. R., 244
Cochran, F. R., 49
Coffey, J. W., 11
Collins, P. W., 30
Colombo, C., 251
Colucci, M., 339
Conese, M., 339
Connor, J. R., 142
Conroy, M. C., 53
Cornwell, D. G., 397
Cowan, A., 264
Crawley, G. C., 110
Čulo, F., 424

Dai, S., 316
Danon, A., 416
Day, R. O., 381
Delander, E.-L., 35
Delmendo, R. E., 132
Depraetere, S., 369
Desa, F. M., 282
Desai, S. N., 211
DiJoseph, J., 220, 223
DiPasquale, G., 66, 129
Dodge, B., 332
Doherty, N. S., 3
Dong, M. K., 53
Doughty, J., 66, 129, 226, 232
Douglas, F. L., 214
Drapeau, G., 138
Dry, J., 203
Dubé, L., 117

Edwards, M. P., 110
Elsbach, P., 274
Emerit, I., 410
Eng, C. P., 220
Ernest, M. J., 16
Evans, C. H., 278, 285

Fantone, J. C., 345
Farmer, S. G., 191
Ferin, M. A., 25
Feuerstein, G., 205
Finch-Arietta, M. B., 49
Fleisher, L. N., 405
Foster, S. J., 110
Fretland, D. J., 5, 30, 172, 178
Frobert, Y., 38
Fruman, D. A., 16
Fumarulo, R., 339

Gaginella, T. S., 5, 30, 172, 178, 397
Galbraith, W., 60
Galey, L., 424
Gamache, D. A., 16
Ganu, V. S., 226
Garst, M., 70
Gelb, M., 106
Georgescu, H. I., 278, 285
Geppetti, P., 376
Gilbertsen, R. B., 53
Giordano, D., 339
Girodeau, J.-M., 110
Glaser, K. B., 89
Goldberg, R. L., 66, 129, 226, 232
Golden, H. W., 148
Gomes, E. L. T., 295
Goodman, R., 113
Grassi, J., 38, 42
Grim, K. S., 145
Grimes, A. M., 405
Gross, J. L., 329
Gu, X., 175, 185
Gundel, R. H., 211
Gunson, D., 214

Hall, N., 239, 324
Hamdan, A., 125
Hanglow, A. C., 11, 81
Hansard, R. M., 178
Harbison, M., 187
Harper, G. P., 332
Harris, R. R., 113
Hartman, D. A., 20, 84
Harvey, A. K., 56
Hashida, R., 242
Haston, W., 129
Hemsén, A., 429
Henderson, B., 324
Henke, M. A., 178
Hidvegi, M. I., 30
Hiyama, Y., 63
Ho, P. P. K., 100
Hope, W. C., 77
Hoshikawa Fujimura, A. Y., 387
Hrubey, P. S., 56
Huang, L., 103
Huizinga, M., 289
Hulkower, K. I., 278

Iverson, L., 181

Jancar, S., 387
Jaurand, M. C., 410
Jeng, A. Y., 46, 232, 251
Joniau, M., 369
Jukic, D., 138

Kanzy, E. J., 161
Katayama, K., 242
Kerr, J. S., 113
Kesterson, J., 117
Kidd, P. R., 113
Kilian, P. L., 187
Kimball, E. S., 329
Kimble, E., 125, 145

ICAM-1 dependent vasculitis 208
IgM-rheumatoid factor 169
IL-1 muteins, effect 60
–, induced inflammation 56
–, synthesis 42
IL-6 42
Immunomodulatory compounds 254
Immunosuppressive agents 165
Indomethacin, effect 46
–, murine progressive ankylosis 257
Inflammatory cell influx 270
–, mediators 178
–, –, release 30
Inositol 1,4,5–trisphosphate mass 16
-interferon, effect 63
Interleukin-1 278
–, cartilage degradation 232,
–, in vivo effects 22
–, induced substance P 46
–, –, inflammation 56
–, inhibition 223
–, intra-articular infusion 220
–, muteins 60
–, production 66
–, receptor antagonist 187
–, synthesis 38, 42
Interleukin-1α 132, 226
Interleukin-1β 217
Interleukin-2 production, inhibition 53
Interleukin 6, effect 42, 369

Keratinocytes 229

Lactobacillus casei 239
Lectinic properties 358
Leukotriene biosynthesis inhibition 145
Leukotriene B_4 42
–, receptor antagonist, effect 172
Lipopolysaccharide 416
5–Lipoxygenase 121
–, activity 117
–, antiinflammatory activity 20
–, enantioselective inhibitors 110
–, inhibitor 73
–, orally active inhibitor 125
–, specific inhibitors 89
LTB_4 biosynthesis 89
Luminal acetic acid 175
Lung cancer 309
LY221068, anti-inflammatory effect 100
LY269415, anti-inflammatory effect 100
Lymphocyte responsiveness 53
–, splenic 11

Macrophage-derived angiogenic activity 350
–, granulocyte 32
–, mediated killing 11
–, pulmonary 197
Mammalian collagenase, intra-articular infusion 220
Mellitin-induced mouse paw edema models 84
Mesenteric mast cell 295
Mesothelial cells 410
Metalloproteinases 324
Methoxyalkyl thiazoles 110
Misoprostol 185
–, effect 30
Monoclonal antibody (MAb) R73 161
Monocyte, contribution 28
–, derived angiogenic activity 350
–, human 30, 42
–, inflammatory mediator release 30
MRL/1 mice, SLE-like autoimmune disease 151
Murine progressive ankylosis 257, 261
Muscle relaxants 302

Naphthoquinones 145
Neuropeptide Y, levels 429
Neutral Red absorption 35
Neutrophil agonist-stimulated 16
–, collagenase activation 8
–, function 25
–, human 32, 89
–, interactions, in vitro model system 197
NSAIDs, ulcerogenic properties 247
Nonsteroidal anti-inflammatory drugs 289
NPC 15437 142

Ocular inflammatory response 405
Oxidants, role 8
Osteoarthritic-like lesions 220

PAF biosynthesis 89
–, penicillamine treatment 405
Pannus formation, angiogenesis 329
Pentraxin 358
Peritoneal macrophages 81
Phagocytes, human 35
Phosphatidylcholine breakdown 32
Phospholipase, inhibitor 70
–, A_2 activities 77, 97, 113
–, –, secretion 81
–, acyl-hydrolytic activity 93
–, human 106
–, putative inhibitors 89
–, D 32
PLA_2 enzymes 103
–, induced mouse paw edema models 84
Platelet activating factor 181
Polyarthritis 239
Polymorphonuclear leukocytes, human 339
Prostacyclin synthesis 416
Prostaglandin, effects 30
–, E2 levels 46
–, synthesis 416
Prostanoid synthesis 397
Protein kinase C 142
–, 60 kDa bactericidal 274
Proteoglycan-induced synovitis 148
Pulmonary macrophages, in vitro model system 197

Rabbit articular chondrocytes 223
–, heterolamellar corneal transplant model 165
Radioligand binding assays, high throughput 132
Rat, acetic acid-induced colitis model 187
–, adjuvant arthritis 129
–, arterial vessels 376
–, bone marrow 429
–, female protein 358
–, monocytes 66
–, pleurisy 251
–, RPAR-induced pleurisy 93, 97
–, thrombocytes 429
–, trachea 200
–, venous vessels 376

Willems, J., 369
Williams, K. M., 381
Wilson, C., 181
Wilson, D., 46, 214, 226, 232, 239
Wilson, L., 187
Winkler, J. D., 103
Wolyniec, W. W., 73
Wong, M., 46, 232, 251
Wright, C. D., 25
Yamatsu, I., 242
Yuan, W., 106
Zhang, H., 397
Zhang, X.-J., 175, 185

Subject Index

A23187–exposed guinea pig 194
Adenosine agonist, standard A_1 selectivity, effect 25
AGN 190383, phospholipase inhibitor 70
Air pouch inflammation, adjuvant-induced 242
Airway reaction, antigen-induced 73, 211
–, edema 203
Allergic encephalomyelitis (EAE), experimental 156, 172
Anaphylatoxins C3a, C5a 345
Angiogenesis 329, 332
Antiallergic drugs 84
Anti-arthritic drugs, effect 56
Anti-CD18 antibody (R15.7), effect 211
Antiflammin-2 77
Antigen arthritis 191
Anti-inflammatory activity 20, 70
–, agent 5
–, compounds 254
–, drugs 84
–, effects 424
Anti-rheumatic drugs 239
Anti-tumoral effects 424
Arachidonic acid cascade 397
Arthritis, adjuvant-induced 11, 63, 81, 148
–, antigen 191
Autoimmune diseases, experimental 161
Azathioprine, extravasation and neutrophil traffikking 244

BI-L-239 73
Biological stains 424
Bovine pulmonary artery endothelial cells 113
Bradykinin 235, 397
–, B_1 receptor 191
–, B_2 receptor antagonists 138
–, induced mucosal inflammatory 200
–, sensitivity 376
Bronchial hyperreactivity, LPS-induced 203
Bronchiolar epithelial proliferation 194
Budesonide 200

C3, complement fragments 5
C5a, complement fragments 5
Canine coronary vasculature 345
Calcitonin gene-related peptide 376
Capsaicin, effect 251
–, sensitivity 376
Carrageenan-induced inflammation 251
Carbohydrate moieties 205
Cartilage degradation 60, 217, 282
–, proteoglycan degradation 214
Casein 175
Cathepsin G 8
Cell, activation inhibitor CI-959 53
–, influx 211
CGS 22745 125
Chemotactic properties 5
Chondrocytes, rabbit articular 223
–, synovial activation 285
Clastogenic factor 410
CRP secretion, stimulation 369
CoA-independent transacylase 103
Compound 48/80 316
Colitis, acetic acid-induced 181, 187,
–, chronic 178
–, inflammation 332
Collagenase production 242
Copper depletion, effects 405
Corticosteroids 20, 165
Cotton-top tamarins, inflammation mediators 178
Crystal-neutrophil interaction 38
Cyclooxygenase 121, 397
Cytokine interactions 285
–, production 49
35kDa cytosolic substrate 278

D49 PLA_2-induced mouse paw edema models 84
15–Deoxyspergualin (15–DOS) 151, 156
Dexamethasone 46, 369
Diclofenac metabolites 135

Econazole, inhibitory effect 387
Eicosanoid biosynthesis 20
–, production 81
Enantiomers, pharmacokinetic 381
Encephalomyelitis, allergic 156, 172
Endothelial cell 113
–, in vitro model system 197
Estrogens, effect 282

Ferrocytochrome C oxidation 393
Fibroblasts 229
–, FMLP, sensitivity 376
–, growth factor 217
Formalin-induced edema 264

Glucocorticoids 20, 165, 416
Granulocyte-macrophage, colony-stimulating factor (GM-CSF) 32

Heat shock peptide, synthetic mycobacterial 148
HepG2 cells 369
Histamine 175
–, intradermal 309
Histopathological scoring system 239
Hydrogen peroxide 393
3α-hydroxysteroid dehydrogenase 289

Ia expression, in vivo effects 66
Ibuprofen, pharmacokinetics 381

Kingston, J. F., 110
Knihinicki, R. D., 381
Koch, A. E., 350
Kontny, M., 73
Kowalski, T., 125, 145
Kownatzki, E., 393
Krug, H. E., 257, 261
Kulkarni, P., 165
Kunkel, S. E., 345
Kurrle, R., 161

Ladhoff, A.-M., 358
LaPlante, A. M., 73
Lauzière, M., 117
Lazaro, E. J., 28
Lazer, E. S., 73
Lee, G., 70
Lee, W., 125
Lefort, J., 203
Lehman, T. J. A., 239
Leibovich, S. J., 350
Lesch, M. E., 25
Letts, L. G., 73, 211
Levin, S., 5, 172
Levy, A., 410
Levy, J. H., 302
Lewin, A. C., 20, 84, 235
Lin, C. W., 285
Little, J., 187
Lock, Y. W., 89
Lucchesi, B. R., 345
Lugay, J. R., 84
Lundberg, J. M., 429
Lussier, A., 38

Macchia, W. M., 145
Mahowald, M. L., 257, 261
Maloff, B. L., 132
Maniglia, C. A., 148
Mantegna, L. R., 113
Manzini, S., 376
Marazzini, L., 309
Marinari, L. R., 93, 97
Marshall, L. A., 106
Marušič, M., 424
Mastropasqua, B., 309
Mazza, P., 309
McGahan, M. C., 405
McMillan, B. A., 191, 229
McMillan, R. M., 110, 121
Meeker, S. N., 191
Melton, R., 226
Mezrich, R. S., 214
Médicis, R. de, 38
Millberg, B.-I., 429
Miller, M. J. S., 175, 185
Miller-Larsson, A., 200
Montemurro, P., 339
Morgan, D. W., 81
Murthy, S. N. S., 244

Naccache, P. H., 38
Nakajima, H., 63
Nantel, F., 138
Neale, R., 125
Noonan, T. C., 211
Nugel, E., 358

O'Byrne, E., 46, 214, 226, 232, 239
O'Donnel, S. R., 200
Ohia, E., 165
Olchowy, T. W. J., 197
Olsen, N. J., 169
Ooi, C. E., 274

Panetta, J. A., 100
Pastor, G., 125, 251
Patel, B. J., 77
Paul, P. K., 214
Pawlowski, J., 289
Pelucchi, A., 309
Penning, T. M., 289
Peppard, J., 46, 66, 129
Pernow, J., 429
Perretti, F., 376
Peterson, C., 35
Pfeilschifter, J., 135
Pfister, C., 358
Pignatello, M., 187
Piper, P. J., 211
Polverini, P. J., 350
Poubelle, P. E., 32, 38, 42
Prajgrod, G., 416
Pratta, M. A., 60
Proudman, K. E., 121

Quagliata, F., 66

Rahleb, N.-E., 138
Ranges, G. E., 148
Rauchle, K. L., 200
Raychaudhuri, A., 125, 251
Regoli, D., 138
Riccardi, S., 339
Roberge, C. J., 38
Roberts, E. D., 239
Rola-Pleszczynski, M., 42
Roland, D. M., 145
Rossi, A. M., 295
Rothlein, R., 211
Rothschild, A. M., 295
Rouissi, N., 138
Rubin, A. S., 239
Rubin, P., 117
Rule, B. L., 60

Sabolvič, D., 424
Sadowska-Krowicka, H., 175, 185
Sagi-Eisenberg, R., 278
Saint-Etienne, L., 410
Sallmann, A., 135
Schade, R., 358
Schenkelaars, E. J., 66, 129
Schmolze, D., 187
Schorlemmer, H. U., 151, 156, 161
Schrier, D. J., 25
Schultheis, A. H., 270
Schumacher, W. A., 345
Schweizer, A., 135
Seiler, F. R., 151, 156, 161
Semeraro, N., 339
Shadle, J. K., 100

Sharma, S. D., 197
Shatzen, E. M., 217
Shearer, B. G., 142
Shone, R. L., 172
Silbaugh, S. A., 194
Simke, J. P., 46
Singh, H. N., 66, 129
Sirois, P., 117, 387
Skotnicki, J. S., 223
Somogy, L., 424
Spillert, C. R., 28
Srivastava, A., 181, 187
Stadel, J., 205
Stankova, J., 42
Stearns, C., 211
Stengel, P. W., 194
Stevens, P., 217
Stevens, T. M., 113
Strorer, B., 205
Sullivan, J. P., 142
Sung, C.-M., 103
Sung, C. P., 205
Symington, J., 187

Takamori, H., 63
Tavares de Lima, W., 387
Teal, G. P., 169
Teixeira, C. F. P., 387
Thomas, T. K., 181, 187
Thompson, R. C., 187
Tomchek, L. A., 20, 84
Tousignant, C., 138
Towner, R. D., 100
Tramontana, M., 376
Traub, L. M., 278
Tsukada, W., 63

Uhrich, S., 393

Vargaftig, B. B., 203
Vincent, D., 203
Vries, G. W. de, 70

Walker, B., 302
Wallace, J. L., 247
Walsh, R. E., 30, 178
Walter, T. L., 235
Wang, J. Z., 214
Ward, J., 220
Wasley, J., 125
Webb, R. C., 345
Wegner, C. D., 73
Weichman, B. M., 93, 97, 235
Weis, W., 181
Weiss, J., 274
Wells, C., 220
Wenk, P., 135
Wenzel, M., 70
Wheeler, L. A., 70
Wheeler-Aceto, H., 264
White, D., 125
White, D. H., 145
Widomski, D. L., 5, 30, 172, 178
Wiesenberg-Boettcher, I., 135
Wieslander, E., 35
Wilburn, D. J., 53
Will, P. C., 181, 187

Respiratory burst 339
Retinoids 339
Rheumatoid arthritis 169

SC-41930, anti-inflammatory agent 5
–, effect 172
Shwartzman response 208
SLE-like autoimmune disease 151
Splenic lymphocytes 11
Substance P, interleukin-1–induced 46
–, level 232, 251
Sucralfate 229
Sympathoadrenal system 429
Synovial plasminogen activator activity 226
–, protein kinase C 278

Target enzyme 289
T-cell receptor (TCR) anti-rat 161
Tenidap 121
Tepoxalin, ulcerogenic properties 247
Thiazoles, methoxyalkyl 110
Thiol-containing compounds 350
Thrombotic potential 28
Thromboxanes, release 387
Tolfenamic acid 121
Triamcinolone, effect 46
Tumor necrosis factor (TNF-a) 132, 205

U937 cells 205

Vascular endothelium, in vitro 205
Vascular smooth muscle 191
Ventricular arrhythmias 316
Vinblastine effects 429

WY-46,135 223
WY-48,989 223

Zileuton (A-64077), effect 117